Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD160 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD160 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD160 Products |
| Gene Delivery | CD160 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD160 Products |
| Benchmark Ab | Anti-CD160 (Sequence of Clinical Benchmarks) Recombinant positive control. |
View CD160 Products |
| Validator | CD160 siRNA Set For knockdown verification. |
View CD160 Products |
| Related Target A | HVEM (TNFRSF14) The primary ligand for CD160; critical for mapping checkpoint blockade. |
View HVEM Products |
| Related Target B | BTLA Competes with CD160 for HVEM binding; essential for selectivity profiling. |
View BTLA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPI-anchor conformation preservation | Lentivirus-driven full-length expression for stable cell lines, preserving native membrane topology. |
| Ligand complexity (HVEM/BTLA/CD160 cross-reactivity) | HEK293-expressed ECD-Fc proteins ensuring native glycosylation patterns for precise SPR binding kinetics. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD160 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD160 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and combination therapies targeting the HVEM/BTLA/CD160 pathway. As first-generation therapies reach the clinic, the next wave of R&D is targeting the dual nature of CD160 as both an inhibitory checkpoint on T cells and an activating receptor on NK cells to maximize anti-tumor efficacy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Innate Pharma, Elpiscience | Solid Tumors, Hematological Malignancies | Blocking assays requiring high-purity CD160 ECD-Fc to disrupt CD160-HVEM binding. |
| Bispecific Antibody (e.g., CD160 x PD-1) | Biotech Innovators | Refractory Solid Tumors | Simultaneous binding validation requiring stable cell lines expressing both targets. |
| NK Cell Engager | Academic & Clinical Consortiums | Advanced Melanoma, NK-cell Lymphoma | Activation assays requiring conformationally intact CD160 on target cells via lentiviral transduction. |